Visit https://www.peervoice.com/DYT860 to view the entire programme with slides. After completing “Seizing the Moment to Improve Outcomes in Melanoma: When and in Whom Should We Consider Adjuvant Therapy?”, participants will be able to: Describe current prognosis for patients with stage III resected melanoma and the rationale for adjuvant treatment; Illustrate the impact of adjuvant immunotherapy treatment on patient outcomes, based on the evidence, in stage III resected melanoma.